Trial Profile
Phase I Exploratory Study of Panobinostat IV in Combination With Bortezomib in Relapsed/Refractory Multiple Myeloma Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Apr 2013 Planned end date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 05 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.